SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02940990 |
|
Recruitment Status : Unknown
Verified November 2016 by Xiaolong Fu, Shanghai Chest Hospital.
Recruitment status was: Not yet recruiting
First Posted : October 21, 2016
Last Update Posted : December 1, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| NSCLC SBRT GM-CSF | Radiation: SBRT concurrent with GM-CSF Drug: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel | Phase 2 |
Lung cancer is the leading cause of cancer death. Forty percent of patients are diagnosed as metastatic lung cancer, and about 50% of them are pan-negative for driver mutations. The median overall survival(OS) for these patients is 11 months, and maintenance therapy can only prolong 2 months of OS. The NCCN guidelines recommend 4-6 cycles of chemotherapy with or without maintenance chemotherapy.
Published data showed that radiotherapy modulates tumor phenotypes, enhances antigen presentation and tumor immunogenicity. The regression of out-field lesions was termed as "abscopal effect". The combination of radiotherapy with immunotherapeutic agents may promote the host anti-tumor immune response and increase the rate of abscopal effect.Published data showed that abscopal effect appeared in 20%-30% patients with metastatic malignant tumors who were treated with the combination of SBRT and GM-CSF.
The investigators evaluate the efficacy of the combination of SBRT and GM-CSF in the multi-metastatic NSCLC participants who are pan-negative for driver mutations. Patients enrolled will be randomized into two groups. The control group will receive the standard regimen as NCCN recommends. The experimental group will receive both the standard chemotherapy and the extra SBRT to primary lesions or metastatic lesions combined with GM-CSF. The investigators compare progress free survival(PFS) of the two groups.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Study Start Date : | November 2016 |
| Estimated Primary Completion Date : | December 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Group A
Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy. After that, clinical observation or maintenance chemotherapy will be given.
|
Drug: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
two-drug regimen |
|
Experimental: Group B
Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy. However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
|
Radiation: SBRT concurrent with GM-CSF
SBRT and GM-CSF 125ug/m2 for 14 days Drug: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel two-drug regimen |
- Progress Free Survival (PFS) [ Time Frame: 2 years ]
- Overall Survival （OS） [ Time Frame: 2 years ]
- Incidence of treatment-related adverse events [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically proven non-small-cell lung cancer.
- Stage IV according to UICC stage system(version 7,2009).The number of metastatic lesions>5
- Pan-negative for driver mutations including EGFR ALK ROS1 c-MET
- At least Three evaluable lesions among which at least two must be suitable for SBRT.
- ECOG performance status 0-2.
- Expected lifespan ≥3 months.
- No brain metastasis in MRI.
- No liver metastasis in abdominal CT or MRI.
- No malignant pleural effusion or pericardial effusion from chest CT and/or pathology.
- Stable lab values: Hematological:
Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥100×109/L, Hemoglobin ≥9 g/dL Renal: Creatinine OR Measured or calculated creatinine clearance (CrCl) (glomerular filtration rate [GFR] can also be used in place of creatinine or CrCl) ≤1.5× the upper limit of normal (ULN) OR ≥60 mL/min for patient with creatinine levels >1.5× institutional ULN Hepatic: Total bilirubin ≤1.5×ULN OR Direct bilirubin ≤ULN for patients with total bilirubin levels >1.5×ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN OR ≤5×ULN for patients with liver metastases ,globulin≥20 g/L, albumin≥30 g/L.
- Able to understand and give written informed consent and comply with study procedures.
Exclusion Criteria:
- Any unstable systemic disease, including active infection, uncontrolled high blood pressure, unstable angina, newly observed angina pectoris within the past 3 months, congestive heart failure (New York heart association (NYHA) class II or higher), myocardial infarction onset six months before included into the group, and severe arrhythmia, liver, kidney, or metabolic disease in need of drug therapy.
- Previously diagnosed with immunodeficiency disease.
- Human immunodeficiency virus (HIV) infection.
- Women in pregnancy or lactation .
- Patients with mental illness, considered as "can't fully understand the issues of this research".
- other Cancer history.
- Histologically confirmed small cell carcinoma or other non NSCLC compositions in the cancer tissue.
- Brain metastasis or liver metastasis or malignant pleural effusion or pericardial effusion.
- Allergy of rhGM-CSF and its accessories.
- Contraindications to GM-CSF treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02940990
| China, Shanghai | |
| Shanghai Chest Hospital | |
| Shanghai, Shanghai, China | |
| Contact: Xiaolong Fu, PhD +862122200000 ext 3602 xlfu1964@126.com | |
| Responsible Party: | Xiaolong Fu, Director, Department of Radiation Oncology, Shanghai Chest Hospital |
| ClinicalTrials.gov Identifier: | NCT02940990 |
| Other Study ID Numbers: |
SCHLC007 |
| First Posted: | October 21, 2016 Key Record Dates |
| Last Update Posted: | December 1, 2016 |
| Last Verified: | November 2016 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
Gemcitabine Paclitaxel Etoposide Vinorelbine Docetaxel Albumin-Bound Paclitaxel Carboplatin Pemetrexed Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators |
Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Topoisomerase II Inhibitors Topoisomerase Inhibitors Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |